ReviewTranslational lung cancer research2019
Current landscape of palliative radiotherapy for non-small-cell lung cancer.
Review in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer.International journal of molecular sciences · 2026Article
- Selenium-Curcumin-PEG Nanoparticles Radiosensitization for Intensity-Modulated Radiation Therapy of Lung Tumor Cells:Journal of biomedical physics & engineering · 2026Article
- Role of radiotherapy in the treatment ofTherapeutic advances in medical oncology · 2026Review
- RadiotherapyTranslational lung cancer research · 2025Article
- Efficacy and safety of high-dose hypofractionated palliative radiotherapy (40 Gy in 10 daily fractions) for non-small cell lung cancer.Radiation oncology journal · 2025Article
- Lung metastases.Nature reviews. Disease primers · 2025Review
- Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany.BMC pulmonary medicine · 2025Article
- Outcomes of patients receiving urgent palliative radiotherapy for advanced lung cancer: an observational study.BMC palliative care · 2024Observational
- Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities.Advances in respiratory medicine · 2024Review
- Dose-Volume Constraints Parameters for Lung Tissue in Thoracic Radiotherapy Following Immune Checkpoint Inhibitor Treatment.Journal of inflammation research · 2024Article
- Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.Journal of functional biomaterials · 2023Review
- Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review.International journal of molecular sciences · 2023Review
- Dyspnea in patients with stage IV non-small cell lung cancer: a population-based analysis of disease burden and patterns of care.Journal of thoracic disease · 2023Article
- Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review.Translational cancer research · 2023Review
- Clinical Outcomes of Patients Treated with Short-course Palliative Radiotherapy in the First Year of the COVID-19 Pandemic: A Single Institution Experience.Acta medica Philippina · 2023Article
- Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine.Frontiers in medicine · 2023Review
- Article
- Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung Adenocarcinoma.Frontiers in oncology · 2022Article
- Article
- Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation.Clinical epidemiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial brachytherapy (EBB), the interest of concomitant treatments (chemotherapy and immunotherapy), and the role of RT in lung cancer emergencies with palliative intent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.